vamotinib   Click here for help

GtoPdb Ligand ID: 9792

Synonyms: compound 1 (Table 1) [WO2012173521] | PF-114 | PF114
Compound class: Synthetic organic
Comment: Vamotinib (PF-114) is a third generation BCR-ABL kinase inhibitor [2-3]. It was designed to target wild-type resistance mutations in BCR-ABL (including the T315I gatekeeper mutation) in order to overcome drug resistance in Philadelphia chromosome positive (Ph+) leukemias. The chemical strucure is claimed in patent WO2012173521 where it is the first compound listed in Table 1 of the patent [1]. Off-targets identified by kinase profile screening include ABL2/ARG, DDR1, DDR2, FMS, FRK/PTK5, LCK, LYN, LYNB, PDGFRα and RET which had <10% residual activity when exposed to 100 nM of inhibitor [3]. We matched PF-114's chemical structure to the INN 'vamotinib' that was released in the WHO's proposed INN list 127 (21 July 2022).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 65.77
Molecular weight 532.22
XLogP 7.11
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1nnc2n1cccc2)C
Isomeric SMILES CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1nnc2n1cccc2)C
InChI InChI=1S/C29H27F3N6O/c1-20-6-7-22(17-21(20)9-11-27-35-34-26-5-3-4-12-38(26)27)28(39)33-24-10-8-23(25(18-24)29(30,31)32)19-37-15-13-36(2)14-16-37/h3-8,10,12,17-18H,13-16,19H2,1-2H3,(H,33,39)
Bioactivity Comments
PF-114 inhibits the ABL T315I gatekeeper mutation with an IC50 of 0.78 nM [3] (IC50 values for inhibition of a number of other ABL mutants are provided in Table 1 [3]). In a kinase profile screen PF-114 (100 nM) inhibited 11 kinases by > 90%. In contrast the ABL inhibitors ponatinib, dasatinib and nilotinib inhibited 47, 36 and 4 kinases respectively at the same concentration [3]. PF-114 inhibits growth of Ba/F3 cells expressing native and resistance mutant BCR/ABL and Ph+ patient-derived cell lines in vitro and is active in xenograft models [2].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ABL proto-oncogene 1, non-receptor tyrosine kinase Hs Inhibitor Inhibition 9.3 pIC50 - 3
pIC50 9.3 (IC50 4.9x10-10 M) [3]
Description: Inhibition of native ABL kinase activity.